Key facts
- It has raised $1.2M; the latest was Later Stage VC in Mar 2026.
- Notable investors include Tech Incubator Program for Startup, Future Science and Technology Holdings, Hallym University Technology Holdings, Hisstory Venture Investments, Mirae Science and Technology — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for D&C Biotechnologies
- ·The full record, as it builds
Funding rounds
No funding rounds for D&C Biotechnologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About D&C Biotechnologies
Operator of a biotechnology company intended to develop urine chemistry analysis alternatives. The company aims to solve the problem of contamination, infection, and inconvenience of the test process of the existing urine test method used in medical settings around the world, enabling medical personnel to easily undertake tests while ensuring convenience and safety.
- Sector
- Healthcare
- HQ
- Daejeon, South Korea
- Founded
- 2021
- Employees
- 6
- Website
- dncbiotechnology.com/
- Ownership
- Privately Held (backing)
D&C Biotechnologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in D&C Biotechnologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on D&C Biotechnologies in its N-PORT filings yet. We sweep new filings monthly.